Concept information
Preferred term
Prazosin
Type
-
mesh:Descriptor
Definition
- A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.
Broader concept
Narrower concepts
Entry terms
- 19216-56-9 (Prazosin)
- 19237-84-4 (Prazosin Hydrochloride)
- Furazosin
- Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-
- X0Z7454B90
- XM03YJ541D
Allowable Qualifier(s)
- administration & dosage (Qualifier)
- adverse effects (Qualifier)
- agonists (Qualifier)
- analogs & derivatives (Qualifier)
- analysis (Qualifier)
- antagonists & inhibitors (Qualifier)
- blood (Qualifier)
- cerebrospinal fluid (Qualifier)
- chemical synthesis (Qualifier)
- chemistry (Qualifier)
- classification (Qualifier)
- economics (Qualifier)
- history (Qualifier)
- immunology (Qualifier)
- isolation & purification (Qualifier)
- metabolism (Qualifier)
- pharmacokinetics (Qualifier)
- pharmacology (Qualifier)
- poisoning (Qualifier)
- radiation effects (Qualifier)
- standards (Qualifier)
- supply & distribution (Qualifier)
- therapeutic use (Qualifier)
- toxicity (Qualifier)
- urine (Qualifier)
Pharmacological Action(s)
In other languages
-
French
-
19216-56-9 (Prazosin)
-
19237-84-4 (Prazosin Hydrochloride)
-
Piperazine, 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)-
-
X0Z7454B90
-
XM03YJ541D
URI
http://data.loterre.fr/ark:/67375/JVR-WC1RVRK5-1
{{label}}
{{#each values }} {{! loop through ConceptPropertyValue objects }}
{{#if prefLabel }}
{{/if}}
{{/each}}
{{#if notation }}{{ notation }} {{/if}}{{ prefLabel }}
{{#ifDifferentLabelLang lang }} ({{ lang }}){{/ifDifferentLabelLang}}
{{#if vocabName }}
{{ vocabName }}
{{/if}}